Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from

Agilent Announces Cash Dividend of 18 Cents Per Share
Agilent Announces Cash Dividend of 18 Cents Per Share


Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on Oct. 28, 2020, to all shareholders of record as of the close of

Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic


DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic


DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences


Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas


As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas


As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on

Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)


Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for

Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System


Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using

Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System


Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using

Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System


Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics


Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company

Seattle Genetics: Megadeal mit Merck & Co!
Seattle Genetics: Megadeal mit Merck & Co!

Zu den größten Gewinnern am US-Aktienmarkt zählt heute die Aktie des Biotechunternehmens Seattle Genetics (WKN: 602322). Grund hierfür ist ein milliardenschwerer Megadeal mit dem ebenfalls

Seattle Genetics: Megadeal mit Merck & Co!
Seattle Genetics: Megadeal mit Merck & Co!

Zu den größten Gewinnern am US-Aktienmarkt zählt heute die Aktie des Biotechunternehmens Seattle Genetics (WKN: 602322). Grund hierfür ist ein milliardenschwerer Megadeal mit dem ebenfalls

Pfizer Hosts Virtual Investor Day
Pfizer Hosts Virtual Investor Day


Pfizer Inc. (NYSE: PFE) will host its virtual Investor Day today and tomorrow: Monday, September 14, 2020 from 1:00 p.m. EDT to 3:45 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to

Pfizer Hosts Virtual Investor Day
Pfizer Hosts Virtual Investor Day


Pfizer Inc. (NYSE: PFE) will host its virtual Investor Day today and tomorrow: Monday, September 14, 2020 from 1:00 p.m. EDT to 3:45 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to

STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial
STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that patient enrollment

NanoString Launches Whole Transcriptome Atlas under GeoMx Technology Access Program and Names First GeoMx Premier Access Sites
NanoString Launches Whole Transcriptome Atlas under GeoMx Technology Access Program and Names First GeoMx Premier Access Sites


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the establishment of the GeoMx Premier Access Sites

Gilead schluckt Immunomedics: +108% nach neuer Biotech-Übernahme
Gilead schluckt Immunomedics: +108% nach neuer Biotech-Übernahme

Biotech bleibt heiß: Mit der Übernahme des Krebsspezialisten Immunomedics (WKN: 872983) durch den Pharmariesen Gilead Sciences (WKN: 885823) feiert der Sektor eine weitere Knallerstory. Das Angebot

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial


Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial


Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the J.P. Morgan 11th Annual U.S

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the J.P. Morgan 11th Annual U.S